Development and characterization of folate anchored Saquinavir entrapped PLGA nanoparticles for anti-tumor activity

References

• Navia MA, Fitzgerald PM, McKeever BM, et al. Three-dimensional structure of the aspartyl protease from human immunodeficiency virus HIV-1. Nature 1989;337:615–20
   PubMed Web of Science ®Google Scholar
• Ikezoe T, Daar ES, Hisatake J, et al. HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. Blood 2000;96:3553–9
   PubMed Web of Science ®Google Scholar
• Pati S, Pelser CB, Dufraine J, et al. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 2002;99:3771–9
   PubMed Web of Science ®Google Scholar
• Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002;8:225–32
   PubMed Web of Science ®Google Scholar
• Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004;56:1649–59
   PubMed Web of Science ®Google Scholar
• Jain S, Kesharwani P, Tekade RK, Jain NK. One platform comparison of solubilization potential of dendrimer with some solubilizing agents. Drug Dev Ind Pharm 2014. [Epub ahead of print]. DOI: 10.3109/03639045.2014.900077
   Google Scholar
• Gupta U, Dwivedi SK, Bid HK, et al. Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells. Int J Pharm 2010;393:185–96
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Tekade RK, Gajbhiye V, et al. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomed Nanotech Biol Med 2011;7:295–304
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Tekade RK, Jain NK. Dendrimer generational nomenclature: the need to harmonize. 2015. [Epub ahead of print]. doi:10.1016/j.drudis.2014.12.015
   Google Scholar
• Niu X, Zou W, Liu C, et al. Modified nanoprecipitation method to fabricate DNA-loaded PLGA nanoparticles. Drug Dev Ind Pharm 2009;35:1375–83
   PubMed Web of Science ®Google Scholar
• Barichello JM, Morishita M, Takayama K, Nagai T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm 1999;25:471–6
   PubMed Web of Science ®Google Scholar
• Kesarwani P, Jain K, Tekade RK, et al. Spectrophotometric estimation of Paclitaxel. Int J Adv Pharm Sci 2011;2:29–32
   Google Scholar
• Mishra V, Kesharwani P, Jain NK. Functionalized polymeric nanoparticles for delivery of bioactives. Nanobiomed 2014;3:91–123
   Google Scholar
• Dubey M, Kesharwani P, Tiwari A, et al. Formulation and evaluation of floating microsphere containing anti diabetic drug. Int J Pharm Chem Sci 2012;1:475–9
   Google Scholar
• Kesharwani P, Tekade RK, Jain K, Jain NK. Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer. Biomaterials 2014;35:5539–48
   PubMed Web of Science ®Google Scholar
• Birdhariya B, Kesharwani P, Jain NK. Effect of surface capping on targeting potential of folate decorated poly (propylene imine) dendrimers. Drug Dev Ind Pharm 2014. [Epub ahead of print]. DOI: 10.3109/03639045.2014.954584
   Google Scholar
• Mehra NK, Jain NK. Development, characterization and cancer targeting potential of surface engineered carbon nanotubes. J Drug Target 2013;21:745–58
   PubMed Web of Science ®Google Scholar
• Thakur S, Kesharwani P, Tekade RK, Jain NK. Impact of pegylation on biopharmaceutical properties of dendrimers. Polymer 2015;59:67–92
   Google Scholar
• Boddu SH, Vaishya R, Jwala J, et al. Preparation and characterization of folate conjugated nanoparticles of doxorubicin using PLGA–PEG–FOL polymer. Med Chem 2012;2:68–75
   Google Scholar
• Mody N, Tekade RK, Mehra NK, et al. Dendrimer, liposomes, carbon nanotubes and PLGA nanoparticles: one platform assessment of drug delivery potential. AAPS PharmSciTech 2014;15:388–99
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Iyer AK. Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery. Drug Discov Today 2014. [Epub ahead of print]. doi:10.1016/j.drudis.2014.12.012
   Google Scholar
• Muruganeshan SK, Subramaniyan G, Averineni RK, et al. PEGylated PLGA nanoparticulate delivery of docetaxel: synthesis of diblock copolymers, optimization of preparation variable formulation characteristics and in vitro release studies. J Biomed Nanotechnol 2007;3:52–60
   Web of Science ®Google Scholar
• Mehra NK, Verma AK, Mishra PR, Jain NK. The cancer targeting potential of d-α-tocopheryl polyethylene glycol 1000 succinate tethered multi walled carbon nanotubes. Biomaterials 2014;35:4573–88
   PubMed Web of Science ®Google Scholar
• Boddu SH, Jwala J, Chowdhury MR, Mitra AK. In vitro evaluation of a targeted and sustained release system for retinoblastoma cells using Doxorubicin as a model drug. J Ocul Pharmacol Ther 2010;26:459–68
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Tekade RK, Jain NK. Generation dependent safety and efficacy of folic acid conjugated dendrimer based anticancer drug formulations. Pharm Res 2014. [Epub ahead of print]. DOI: 10.1007/s11095-014-1549-2
   Google Scholar
• Zhang L, Chan JM, Gu FX, et al. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2008;2:1696–702
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Tekade RK, Jain NK. Formulation development and in vitro–in vivo assessment of the fourth-generation PPI dendrimer as a cancer-targeting vector. Nanomedicine (Lond) 2014;9:2291–308
   Google Scholar
• Yoo HS, Park TG. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin–PEG–folate conjugate. J Control Rel 2004;100:247–56
   PubMed Web of Science ®Google Scholar
• Choy JH, Jung JS, Oh JM, et al. Layered double hydroxide as an efficient drug reservoir for folate derivatives. Biomaterials 2004;25:3059–64
   PubMed Web of Science ®Google Scholar
• Liang C, Yang Y, You L, et al. Improved therapeutic effect of folate-decorated PLGA–PEG nanoparticles for endometrial carcinoma. Bioorg Med Chem 2011;19:4057–66
   PubMed Web of Science ®Google Scholar
• Akasaka K, Gyimesi-Forras K, Lammerhofer M, et al. Investigations of molecular recognition aspects related to the enantiomer separation of 2-methoxy-2-(1-naphthyl) propionic acid using quinine carbamate as chiral selector: an NMR and FT-IR spectroscopic as well as X-ray crystallographic study. Chirality 2005;17:544–55
   PubMed Web of Science ®Google Scholar
• Yang SJ, Lin FH, Tsai KC, et al. Folic acid-conjugate chitosan nanoparticles enhanced protoporphyrin IX accumulation in colorectal cancer cells. Bioconj Chem 2010;21:679–89
   PubMed Web of Science ®Google Scholar
• Dube D, Francis M, Leroux JC, Winnik FM. Preparation and tumor cell uptake of poly(N-isopropylacrylamide) folate conjugates. Bioconj Chem 2002;13:685–92
   PubMed Web of Science ®Google Scholar
• Ganji F, Abdekhodaie MJ. Synthesis and characterization of a new thermosensitive chitosan–PEG diblock copolymer. Carbohydr Polym 2008;74:435–41
   Web of Science ®Google Scholar
• Rubiana MM, Raul CF. PLGA nanoparticles contain praziquantel: effect of formulation variables on size distribution. Int J Pharm 2005;290:137–44
   PubMed Web of Science ®Google Scholar
• Dodiya SS, Chavhan SS, Sawant KK, Korde AG. Solid lipid nanoparticles and nanosuspension formulation of saquinavir: preparation, characterization, pharmacokinetics and biodistribution studies. J Microencapsul 2011;28:515–27
   PubMed Web of Science ®Google Scholar
• Mukerjee A, Vishwanatha JK. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res 2009;29:3867–76
   PubMed Web of Science ®Google Scholar
• Bolourchian N, Mahboobian MD, Dadashzadeh S. The effect of PEG molecular weights on dissolution behavior of simvastatin in solid dispersions. Iran J Pharm Res 2013;12:11–20
   PubMed Web of Science ®Google Scholar
• Patel R, Patel M. Preparation, characterization, and dissolution behavior of a solid dispersion of simvastatin with polyethylene glycol 4000 and polyvinylpyrrolidone k30. J Disper Sci Tech 2008;29:193–204
   Web of Science ®Google Scholar
• Florea GM, Ficai A, Oprea O, et al. Drug delivery systems based on silica with prolonged delivery of folic acid. Roman J Mater 2012;42:313–16
   Web of Science ®Google Scholar
• Haidary SM, Corcoles EP, Ali NK. Folic acid delivery device based on porous silicon nanoparticles synthesized by electrochemical etching. Int J Electrochem Sci 2013;8:9956–66
   Web of Science ®Google Scholar
• McNeil SE. Unique benefits of nanotechnology to drug delivery and diagnostics. Methods Mol Biol 2011;697:3–8
   Google Scholar
• Sun YN, Wang CD, Zhang XM, et al. Shape dependence of gold nanoparticles on in vivo acute toxicological effects and biodistribution. J Nanosci Nanotechnol 2011;11:1210–16
   PubMed Web of Science ®Google Scholar
• Elbayoumi TA, Torchilin VP. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Euro J Pharm Sci 2007;32:159–68
   PubMed Web of Science ®Google Scholar
• Chen H, Ahn R, Bossche VJ, et al. Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol Cancer Ther 2009;8:1955–63
   PubMed Web of Science ®Google Scholar
• Mansoori GA, Brandenburg KS, Shakeri-Zadeh A. A comparative study of two folate-conjugated gold nanoparticles for cancer nanotechnology applications. Cancers 2010;2:1911–28
   PubMedGoogle Scholar
• Hattori Y, Maitani Y. Folate-linked nanoparticles-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase. Cancer Gene Ther 2005;12:796–809
   PubMed Web of Science ®Google Scholar
• Pajonk F, Himmelsbach J, Riess K, et al. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 2002;62:5230–5
   PubMed Web of Science ®Google Scholar
• Gupta A, Zhang Y, Unadkat JD, Mao Q. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP1/ABCG2). J Pharmacol Exp Ther 2004;310:334–41
   PubMed Web of Science ®Google Scholar
• Weiss J, Rose J, Storch CH, et al. Modulation of human BCRP1 (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 2007;59:238–45
   PubMed Web of Science ®Google Scholar
• Maksimovic-Ivanic D, Mijatovic S, Miljkovic D, et al. The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir independent of Akt. Mol Cancer Ther 2009;8:1169–78
   PubMed Web of Science ®Google Scholar
• Sgadari C, Toschi E, Palladino C, et al. Mechanism of paclitaxel activity in Kaposi’s sarcoma. J Immunol 2000;165:509–17
   PubMed Web of Science ®Google Scholar
• Pyrko P, Kardosh A, Wang W, et al. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res 2007;67:10920–8
   PubMed Web of Science ®Google Scholar
• Holm J, Ingemann Hansen S, Hoier-Madsen M. High-affinity folate binding in human prostate. Biosci Reports 1993;13:99–105
   PubMed Web of Science ®Google Scholar
• Rothweiler F, Michaelis M, Brauer P, et al. Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia 2010;12:1023–30
   PubMed Web of Science ®Google Scholar